Affected infants are symptomatic at birth with hypoketotic hypoglycemia, seizures, cardiomyopathy/arrythmias, liver failure and death occurring within the first few weeks of life, (2) severe infantile (hepatocardiomuscular) form, with symptomatology appearing from 6 to 24 months of life in a similar presentation but less severe than LNF form and (3) myopathic form, which is the least severe type and they become symptomatic in infancy to adulthood with myalgia and weakness following exercise or fasting ( Lethal neonatal form of CPT II remains a challenge in early diagnosis and treatment
It has the strongest clinical evidence for combined fat-loss and lean-mass effects of any peptide on this list
doi: 10.3389/fonc.2026.1680441 Received 06 August 2025 Revised 20 January 2026 Accepted 20 January 2026 Published 03 February 2026 Volume 16 - 2026 Edited by Arumugam Jayakumar, University of Texas MD Anderson Cancer Center, United States Reviewed by Enrico Martin, University Medical Center Utrecht, Netherlands Fei Song, Affiliated Hospital of Nantong University, China Updates Copyright 2026 Zhu, Shen, Yang, Han, Li, Xie, Tan, Lu, Ji and Zhang
Yes, often
Discover our wrap-around support for members on GLP-1 medications What is GLP-1